Skip to main content

Featured

Wall Street Futures Rise Ahead of Thanksgiving Holiday

  US stock futures edged higher on Wednesday as investors looked to extend the market’s recent rally into the Thanksgiving holiday. Dow Jones Industrial Average futures gained 0.2%, S&P 500 futures rose 0.2%, and Nasdaq 100 futures climbed 0.3% . The move follows a strong session on Tuesday, when the Dow surged more than 660 points (1.4%) , marking its third consecutive day of gains. Tech stocks continued to drive momentum, with Alphabet closing at record highs after reports that Meta may adopt Google’s TPU chips in the coming years. Meanwhile, Nvidia shares slipped over 2.5% as competition in the AI chip space intensified. Investors are also keeping a close eye on the Federal Reserve. Markets are currently pricing in an 85% probability of a quarter-point rate cut in December , which has helped bolster optimism. Lower Treasury yields and easing inflation pressures have further supported the bullish sentiment. Through the first two trading days of this holiday-shortened we...

article

Pharmacare in Canada: A Dream or a Reality?

 


The fate of Canada's pharmacare plan is uncertain as the federal government faces challenges in implementing a universal drug coverage program, even if a bill to create one passes in Parliament. Bill C-213, the Canada Pharmacare Act, aims to establish a national framework for pharmacare that would ensure all Canadians have access to prescription drugs based on their medical needs, not their ability to pay. 

However, the bill does not specify how the program would be funded, administered or negotiated with the provinces and territories, leaving many questions unanswered about the feasibility and cost-effectiveness of pharmacare. Some experts and stakeholders have expressed doubts about whether Ottawa has the political will, the constitutional authority and the fiscal capacity to deliver on its promise of pharmacare, especially in the wake of the COVID-19 pandemic that has strained the health care system and the public purse.

Comments